Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

500
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
500
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

305
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
305
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

68
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
68
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

49
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
49

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal of cardiac failure·2026
Same author

Pericardiocentesis vs. surgical pericardial window for first occurrence of malignancy-related pericardial effusion: a meta-analysis of retrospective studies.

European heart journal open·2026
Same author

High sensitivity troponin-I and myocardial injury after noncardiac surgery for cancer in a large prospective cohort.

BMC anesthesiology·2025
Same author

General practice professionals' perspectives on cardiovascular risk assessment in patients diagnosed with mental health disorders: an embedded mixed-methods study.

Irish journal of psychological medicine·2025
Same author

Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM.

Journal of the American College of Cardiology·2025
Same author

Characterization of anticancer therapy-induced microvascular dysfunction in patients with breast cancer supports targeted intervention.

JCI insight·2025

Related Experiment Video

Updated: Nov 8, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.5K

Circulating Biomarkers for Cardiotoxicity Risk Prediction.

Fei Fei Gong1, Gregory J Cascino1, Gillian Murtagh2

  • 1Division of Cardiology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 600, Chicago, IL, 60611, USA.

Current Treatment Options in Oncology
|April 18, 2021
PubMed
Summary

Circulating biomarkers like troponins and natriuretic peptides may help predict cardiotoxicity in cancer survivors. This review explores their role in identifying patients at risk from cancer therapies.

Keywords:
BiomarkersCancer therapyCardiotoxicityRisk prediction

More Related Videos

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

36.9K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.9K

Related Experiment Videos

Last Updated: Nov 8, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.5K
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

36.9K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.9K

Area of Science:

  • Cardiology
  • Oncology
  • Biomarker Discovery

Background:

  • Cancer survival rates have improved, increasing the incidence of cardiovascular disease in survivors.
  • Cardiovascular disease is now a major cause of adverse outcomes in cancer survivors.
  • Cancer therapeutics-related cardiac dysfunction is a known issue, with newer therapies presenting diverse cardiotoxicities.

Purpose of the Study:

  • To review the evidence for using circulating biomarkers in predicting cardiotoxicity associated with cancer therapies.
  • To explore the potential of biomarkers in identifying cancer patients at risk of cardiovascular complications.

Main Methods:

  • Literature review of studies on circulating biomarkers and cancer therapy-induced cardiotoxicity.
  • Analysis of evidence for troponins and natriuretic peptides in cardiotoxicity risk prediction.
  • Investigation of emerging biomarkers for cardiotoxicity.

Main Results:

  • Troponins and natriuretic peptides have the most substantial evidence base for predicting cardiotoxicity risk.
  • Various other circulating biomarkers are under investigation for their predictive value.
  • Identifying patients at risk for cardiotoxicity from novel cancer therapies remains a challenge.

Conclusions:

  • Circulating biomarkers represent a promising approach for identifying patients at risk of cardiotoxicity from cancer therapies.
  • Further research is needed to establish optimal biomarker strategies for cardiotoxicity surveillance.
  • Biomarker-guided management could improve cardiovascular outcomes in cancer survivors.